Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

31 Aug 2017

The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.

3d illustration of T cells or cancer cells — Novartis's Kymriah will be reimbursed under a groundbreaking arrangement

Novartis AG's newly-approved CAR-T treatment for childhood leukemia, Kymriah (tisagenlecleucel), will be reimbursed based on outcomes under a groundbreaking arrangement between the manufacturer and the Centers for Medicare and Medicaid Services.

Kymriah was cleared by FDA Aug. 30 for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia that...